Startseite > Publikationen

Publikationen

2025 Publikationen
Albrecht K, Thiele K, Alexander A, Aringer M, Detert J, Eidner T, Feuchtenberger M, Henes JC, Karberg K, Kiltz U, Köhler B, Krause A, Richter JG, Späthling-Mestekemper S, Steinmüller M, Zinke S, Strangfeld , Callhoff J.

Jahresbericht 2025 aus der Kerndokumentation der Regionalen Kooperativen Rheumazentren. [Annual report 2025 from the National Database of the Regional Collaborative Rheumatology Centers in Germany].

Z Rheumatol. 2025 May 05 [epub ahead of print] Open Access
Jahresbericht 2025 aus der Kerndokumentation der Regionalen Kooperativen Rheumazentren. [Annual report 2025 from the National Database of the Regional Collaborative Rheumatology Centers in Germany].
Kaiser KM, Raabe J, ToVinh M, Hack G, Ahmad S, Müller NC, Cassella J, Walravens SI, Alfaro P, Arias GL, Kaczmarek DJ, Marwitz T, Goeser F, Nischalke HD, Lutz P, Sommer NM, Vilz T, Toma M, Steiner S, Hommerding O, Oldenburg J, Hölzel M, Kadzik S, Maas A, Eckrich J, Zumfelde P, Shakeri F, Nesic S, Buness A, De Caro E, Becker M, Beyer MD, Ulas T, Aschenbrenner AC, Steinheuer LM, Thurley K, Kroh S, Uecker R, Anja Hauser AE, Gohr FN, Schmidt FI, Wang D, Held K, Baranov O, Geldmacher C, Strassburg CP, Hüneburg R, Krämer B, Nattermann J.

IL-17A-producing NKp44(-) group 3 innate lymphoid cells accumulate in Familial Adenomatous Polyposis duodenal tissue.

Nat Commun. 2025 Apr 25:16(1):3873. Open Access
IL-17A-producing NKp44(-) group 3 innate lymphoid cells accumulate in Familial Adenomatous Polyposis duodenal tissue.
Parhofer KG, Pittrow D, Birkenfeld AL, Fraass U, Hohenstein B, Siegert C, Klotsche , Steinhagen-Thiessen E, Dexl S, Schettler VJJ, Laufs U.

Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study.

Acta Cardiol. 2025 Apr 24:1-11. [epub ahead of print] Open Access
Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study.
1 92 93 94 95 96 225